Pi Yaping, Fan Yanan, Liu Jun, Cheng Xinran, Guo Li, Hu Ruyi, Wang Ruifeng, Xu Gaoran
Department of Thyroid and Breast Surgery, The Central Hospital of Ezhou, Ezhou, China.
Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Robot Surg. 2025 May 7;19(1):207. doi: 10.1007/s11701-025-02367-5.
Benign breast tumors, while noncancerous, can cause significant distress and necessitate efficient treatment methods. Mammotome minimally invasive rotary cutting surgery has emerged as a potential alternative to traditional approaches, promising reduced invasiveness and improved outcomes. This retrospective study, conducted from January 2022 to December 2023 at Ezhou Central Hospital, involved a comparative analysis between two groups: the observation group, treated with Mammotome minimally invasive rotary cutting surgery, and the control group, treated with conventional surgical methods. Key parameters assessed included surgical duration, intraoperative blood loss, incision healing time, hospital stay duration, postoperative complication rates, cosmetic outcomes, and changes in postoperative inflammatory and immune markers (TNF-α, hs-CRP, CD3 + , CD4 + /CD8 + ratios). Statistical significance was determined using appropriate tests, with p values less than 0.05 considered significant. The observation group demonstrated significantly better outcomes in terms of shorter surgical duration, reduced intraoperative blood loss, quicker incision healing, and shorter hospital stays compared to the control group (p < 0.05). In addition, the occurrence of postoperative complications was lower, and the rate of maintaining a good breast shape was higher in the observation group (p < 0.05). The observation group also showed lower levels of postoperative inflammatory markers (TNF-α, hs-CRP) and higher immune markers (CD3 + , CD4 + /CD8 + ratios) post-surgery (p < 0.05). Mammotome minimally invasive rotary cutting surgery is an effective and preferable method for the treatment of benign breast tumors, offering reduced surgical trauma, faster recovery, fewer complications, better cosmetic outcomes, and more favorable postoperative inflammatory and immune responses compared to traditional surgical methods. Despite the retrospective design, the findings suggest that Mammotome surgery may serve as a standard approach in benign breast tumor management, with further prospective research needed to validate these outcomes.
良性乳腺肿瘤虽非癌性，但可引起极大困扰，需要有效的治疗方法。麦默通微创旋切手术已成为传统手术方法的一种潜在替代方案，有望降低侵袭性并改善治疗效果。本回顾性研究于2022年1月至2023年12月在鄂州中心医院进行，涉及两组的对比分析：观察组采用麦默通微创旋切手术治疗，对照组采用传统手术方法治疗。评估的关键参数包括手术时长、术中出血量、切口愈合时间、住院时长、术后并发症发生率、美容效果以及术后炎症和免疫标志物（TNF-α、hs-CRP、CD3 +、CD4 + /CD8 + 比值）的变化。使用适当的检验确定统计学意义，p值小于0.05被认为具有显著性。与对照组相比，观察组在手术时长更短、术中出血量减少、切口愈合更快以及住院时间更短方面表现出显著更好的效果（p < 0.05）。此外，观察组术后并发症的发生率更低，保持良好乳房外形的比例更高（p < 0.05）。观察组术后炎症标志物（TNF-α、hs-CRP）水平也更低，术后免疫标志物（CD3 +、CD4 + /CD8 + 比值）更高（p < 0.05）。与传统手术方法相比，麦默通微创旋切手术是治疗良性乳腺肿瘤的一种有效且更优的方法，具有手术创伤小、恢复快、并发症少、美容效果好以及术后炎症和免疫反应更有利等优点。尽管本研究为回顾性设计，但研究结果表明麦默通手术可能成为良性乳腺肿瘤治疗的标准方法，仍需进一步的前瞻性研究来验证这些结果。
